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ApoptosisProgrammed cell death 5 (PDCD5) plays a crucial role in TP53-mediated apoptosis, but the regulatory mecha-
nism of PDCD5 itself during apoptosis remains obscure. We identiﬁed YY1-associated factor 2 (YAF2) as a
novel PDCD5-interacting protein in a yeast two-hybrid screen for PDCD5-interacting proteins. We found that
YY1-associated factor 2 (YAF2) binds to and increases PDCD5 stability by inhibiting the ubiquitin-dependent
proteosomal degradation pathway. However, knocking-down of YAF2 diminishes the levels of PDCD5 protein
but not the levels of PDCD5 mRNA. Upon genotoxic stress response, YAF2 promotes TP53 activation via associa-
tionwith PDCD5. Strikingly, YAF2 failed to promote TP53 activation in the deletion of PDCD5,whereas restoration
of wild-type PDCD5WT efﬁciently reversed the ineffectiveness of YAF2 on TP53 activation. Conversely, PDCD5 ef-
ﬁciently overcame the knockdown effect of YAF2 on ET-induced TP53 activation. Finally, impaired apoptosis
upon PDCD5 ablation was substantially rescued by restoration of PDCD5WT but not YAF2-interacting defective
PDCD5E4D nor TP53-interacting defective PDCD5E16D mutant. Our ﬁndings uncovered an apoptotic signaling cas-
cade linking YAF2, PDCD5, and TP53 during genotoxic stress responses.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Tumor suppressor TP53 is a critical transcriptional factor and
plays a central role in the regulation of cell cycle, DNA repair, apopto-
sis, senescence, and angiogenesis [1]. The function of TP53 is tightly
controlled by its binding partners and post-translational modiﬁca-
tions [2,3]. Under normal conditions, TP53 is maintained at a low
level by interacting with E3 ubiquitin ligases such as MDM2, Pirh2,
COP1, and ARF-BP1, which mediate TP53 degradation by the ubiqui-
tin–proteasome pathway [4–7]. In contrast, under stress conditions,
TP53 is stabilized by factors such as p300, ATM, and HIPK2 and is ac-
tivated to function as a transcription activator and regulator of
downstream target genes for cell cycle arrest and apoptosis [8–10].
Although much research has uncovered an impressive number of
TP53-interacting proteins, MDM2 and MDMX proteins are mostF2, YY1-associated factor 2; ET,
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hgeun@yuhs.ac (H.-G. Yoon).highlighted as promising targets of cancer therapy [11]. Most small
molecules that directly or indirectly activate the TP53 response are
TP53-MDM2 interaction inhibitors [12]. Although MDM2 inhibitors
are shown to effectively reactivate TP53 in vivo, there are still limited
applications for retainingmutant TP53 or deleted TP53 [13,14]. Thus,
further understanding of the TP53 network could lead to the devel-
opment of selective and potent chemotherapy.
Programmed cell death 5 (PDCD5), formerly designated TFAR19
(TF-1 cell apoptosis related gene-19), is a novel gene from TF-1 cells un-
dergoing cytokine deprivation-induced apoptosis. The gene is widely
expressed in a variety of tissues, although its mRNA expression in fetal
tissue is signiﬁcantly lower than in adult tissue [15]. Recent ﬁndings
demonstrated the role of PDCD5 in the immunoregulation and its
mRNA levels and protein expression are signiﬁcantly decreased in pso-
riasis [16,17].When overexpressed in cancer cell lines, PDCD5 facilitates
apoptosis triggered by certain stimuli and enhances TAJ/TROY-induced
paraptosis-like cell death. When cells are undergoing apoptosis, PDCD5
expression is rapidly upregulated, and the protein is translocated from
the cytoplasm to the nucleus [18]. Restoration of PDCD5 with recombi-
nant protein or an adenovirus expression vector can signiﬁcantly
sensitize different cancers to chemotherapies [19,20]. In addition,
single-nucleotide polymorphisms in the PDCD5 regulatory region are
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Decreased PDCD5 expression has been reported in various human tu-
mors, such as breast cancer [23], hepatocellular carcinoma [24], lung
cancer [22], gastric cancer [25], astrocytic glioma [26], chondrosarcoma,
and ovarian carcinoma [27]. These ﬁndings suggest decreased PDCD5
expressionmay be associatedwith carcinoma formation andmalignant
progression. Recent studies demonstrated that PDCD5 interacts with
Tip60, enhances histone and TP53 K120 acetylation, and promotes
BAX expression, consequently accelerating apoptosis after UV irradia-
tion [28]. PDCD5 enhances TP53 stability by inhibiting MDM2-induced
TP53 ubiquitination, nuclear export and proteasomal degradation [29].
Based on accumulated evidence, PDCD5 likely plays a positive regulato-
ry role in the TP53 pathway. However, the molecular mechanism
PDCD5's regulation during apoptosis remains unclear.
To understand the regulatory mechanism of tumor suppressor
PDCD5during apoptosis, we employed yeast two-hybrid assays to iden-
tify PDCD5's interactingpartners and found that YAF2 binds to PDCD5 in
response to genotoxic stress.We showed that YAF2 selectively increases
the accumulation of PDCD5 protein by inhibiting ubiquitination of
PDCD5. Moreover, knocking-down of YAF2 greatly diminishes PDCD5
stabilization as well as TP53 in response to etoposide (ET). We ﬁnally
demonstrated that YAF2 promotes TP53-mediated genotoxic stress re-
sponse in a PDCD5-dependent manner. Finally, we describe an apopto-
tic signaling cascade linking YAF2, PDCD5, and TP53 during genotoxic
stress responses.
2. Materials and methods
2.1. Generation of Pdcd5ﬂox/ﬂox MEFs, cancer cell culture, and reagents
Human lung adenocarcinoma cell line A549, human colorectal
carcinoma cell line HCT116 (TP53+/+), and HCT116 (TP53−/−)
were purchased from and authenticated by the Korean Cell Line
Bank (Seoul, South Korea) using short tandem repeat analysis.
These cells were used within 6 months of purchases. All cells were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin,
and 0.1 mg/ml streptomycin (Hyclone, Logan, UT, USA) at 37 °C
under 5% CO2. Wild-type and Pdcd5f/fMEF cells were prepared as de-
scribed previously [30]. TheseMEF cells were used for all subsequent
experiments. MEF cells were maintained in DMEM containing 15%
FBS (GIBCO BRL, Gaithersburg, MD, USA) and subcultured 1:3 upon
reaching conﬂuence. For electroporation of MEFs (3rd passage),
5 μg of plasmids was electroporated into a suspension of MEF cells
(2 × 105 cells) using a Neon transfection system (Life Technologies,
Grand Island, NY, USA). Etoposide (ET) and cycloheximide were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA), and MG-132 was
purchased from Calbiochem (Darmstadt, Germany). Etoposide and
MG-132 were prepared in dimethyl sulfoxide (DMSO) (Sigma-Al-
drich). Nutlin3a is from Sigma-Aldrich. Tenovin-6 was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Control cul-
tures received the same amounts of DMSO, and ﬁnal DMSO concen-
trations did not exceed 0.1%. Transient transfection was performed
using Polyexpress (Excel Gene, Rockville, MD, USA).
2.2. Immunoprecipitation (IP) and antibodies
Antibodies against p53 (sc-126), p21, pro-PARP-1 and HAwere pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-
body against γH2AX was purchased from Epitomics (Burlingame, CA,
USA). Antibody against PDCD5 was purchased from Proteintech Group
Inc. (Chicago, IL, USA). FLAG and β-actin antibodies were obtained
from Sigma-Aldrich. Myc, pro-caspase-3, cleaved-caspase-3 antibodies
were purchased from Cell Signaling (Beverly, MA, USA). Cleaved-
PARP-1 (51-6639GR) antibody was purchased from BD Transduction
Laboratories (Lexington, KY, USA). Bax and Puma antibodies werepurchased from Abcam (Cambridge, MA, USA). The antibody against
YAF2 was generated by LabFrontier (Anyang, South Korea) using the
synthetic peptide MGDKKSPTRPKRQPKPSS.
2.3. Yeast two-hybrid screening
The MatchmakerTM Gold Yeast Two-Hybrid System (Clontech
Laboratories, Mountain View, CA, USA) was used for yeast two-
hybrid screening according to the manufacture's protocol with
minor modiﬁcation. Brieﬂy, bait plasmid for PDCD5 (pGBKT7-
PDCD5) was transformed in yeast strain Y2H Gold. Transformants
containing each bait plasmid were mated with the pre-transformed
human Testis cDNA library. From the positive clones showing
growth in minimal medium lacking tryptophan, leucine, adenosine,
and histidine andwith β-galactosidase expression with aureobasidin
A selection, plasmids were harvested, prepared, and identiﬁed by
DNA sequencing.
2.4. RNA isolation and quantitative RT-PCR
Total RNA was extracted using the Trizol reagent following the stan-
dard protocol (TAKARA, Shimogyo-ku, Kyoto, Japan). Then, cDNA was
prepared using random hexamer primers (Chromogen). PCR was per-
formed using the following forward and reverse primers: 5′-GATGGCAT
GGACTGTGGTCA-3′, 5′-GCAATGCCTCCTGCACCACC-3′ (human GAPDH);
5′-GTGGAGAGCATTCCATCCCT-3′, 5′-TGGATGCAGCTTCCTCTCTG-3′
(human CDKN1A); 5′-TCTACTTTGCCAGCAAACTGGTGC-3′, 5′-TGTC
CAGCCCATGATGGTTCTGAT-3′ (human BAX); 5′-GTGTTCCTACCCCC
AATGTGT-3′, 5′-AGGAGACAACCTGGTCCTCAGT-3′(mouse Gapdh);
5′-GGAGCAGCTTGGGAGCG-3′, 5′-AAAAGGCCCCTGTCTTCATGA-3′
(mouse Bax); and 5′-GCCTTAGCCCTCACTCTGTG-3′, 5′-AGCTGGCC
TTAGAGGTGA CA-3′ (mouse Cdkn1a). The concentration of cDNA
was normalized using GAPDH. Quantitative-PCR analyses were per-
formed using SYBR Green PCR master mix reagents and an ABI Prism
7700 sequence detection system (Applied Biosystems, Carlsbad, CA,
USA). All reactions were performed in triplicate. Relative expression
levels and SD values were calculated using the comparative method.
2.5. Adenoviruses and lentiviral shRNAs
For stable knockdown of gene expression, two pairs of oligonucleo-
tides that encode the shRNA against each target MISSION shRNA were
purchased (Sigma-Aldrich). To generate lentiviral particles, the
pLKO.1-PURO PDCD5 or YAF2 plasmid with three plasmids (pMDLg/
pRRE, envelope pRSV-REV and pMD2.G) were co-transfected using li-
pofectamine 2000 (Invitrogen, Grand Island, NY, USA) into the 293FT
cell line. After 48 h incubation, supernatants were collected and ﬁltered
using 0.45 μm-poreﬁlters. TheHCT116or A549 cell linewas then infect-
ed with lentivirus particles. After incubation with virus supernatant for
2 days, cells were selected with 1 μg/ml puromycin (Sigma-Aldrich).
Lentivirus PURO shRNA was generated as a control. Recombinant ade-
noviruses expressing GFP and Cre recombinase were generated as de-
scribed [31]. These constructs were ligated into an E1 shuttle
vector and then linearized with PmeI. The linearized vector was
co-transformed into E. coli BJ 5183 with the pAdEasy1 vector. All vi-
ruses were propagated in 293A cells and puriﬁed by CsCl density
puriﬁcation. Viral particles were calculated at 260 nm absorbance.
The multiplicity of infection was calculated from viral particle num-
bers [32].
2.6. Plasmids
Wild-type, full-length PDCD5, YAF2, YAF2-N terminus, and YAF2-C
terminus constructswere generated by PCR and cloned into the plasmid
vectors pSG5-KF2M1-FLAG, -Myc, or -HA (Sigma-Aldrich), and
pGEX4T-1 (GE healthcare, Piscataway, NJ, USA). ATP1B1, ARRDC5,
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Fig. 2. YAF2 stabilizes PDCD5 in response to genotoxic stress. (A) Knockdown of YAF2 diminishes the effect of MG132 on PDCD5 stability. HCT116 (TP53+/+) cells were transfected with
MG132 or shYAF2 and immunoblotted with indicated antibodies. Representative blots of three independent experiments are shown. (B) YAF2 increases PDCD5 stability in a TP53-depen-
dent manner. HCT116 (TP53+/+) cells were treated with cycloheximide and indicated plasmids for various time periods, and cell lysates were analyzed by Western blotting. Represen-
tative blots of three independent experiments are shown. (C) Knockdown of YAF2 reduces PDCD5 stability. HCT116 (TP53+/+) cells were treated with cycloheximide and shYAF2 for
various time periods, and cell lysates were analyzed by Western blotting. Representative blots of three independent experiments are shown. (D) Overexpression of YAF2 has no effect
on mRNA levels of PDCD5. HCT116 cells were transfected with Flag-YAF2 plasmid or shYAF2. The mRNA levels of indicated genes were analyzed by qRT-PCR. The results are shown as
means ± SD calculated from three independent experiments. (E) Wild-type YAF2, but not YAF2ΔPDCD5, inhibits the ubiquitination of PDCD5. HCT116 (TP53+/+) cells were transfected
with the indicated set of plasmids and/or MG132, and cell lysates were analyzed by Western blotting. Representative blots of three independent experiments are shown.
(F) Knockdown of YAF2 diminishes PDCD5 and TP53 induction in response to genotoxic stresses. HCT116 cells were transfected with the indicated sets of shRNAs and were stimulated
with doxorubicin (50 μM) or cisplatin (50 μM). Dox, doxorubicin; Cisp, cisplatin; ET, etoposide. Representative blots of three independent experiments are shown.
1063S.-Y. Park et al. / Biochimica et Biophysica Acta 1853 (2015) 1060–1072YBX1, STK11IP, NSEP, PDCL3, SYCP1, PCMT1, PLSCR2, UBXN7,
WDR74 were obtained from DNASU Plasmid Repository (Arizona
University, Tempe, AZ, USA). All plasmid constructs were veriﬁed
by DNA sequencing.Fig. 1. YAF2 binds to and selectively increases PDCD5 protein levels in response to genotoxic stre
transfected with the indicated sets of plasmids and were stimulated without or with 50 μM etopo
resentative blots of three independent experiments are shown. (B) Validation of endogenous inte
PDCD5 antibody and subsequently immunoblotted with indicated antibodies. Representative blo
but not its paralog RYBP. Cellswere transfectedwith indicated plasmids.Whole cell lysateswere im
ies. Representative blots of three independent experiments are shown. (D)Wild-type YAF2, but n
were transfectedwith the indicated sets of plasmids.Whole cell lysates were immunoblottedwith
(E) Validation of interaction between YAF2 and PDCD5. Cells were transfected with the indicate
methods. Representative images of three independent experiments are shown. Bar scale = 10 μ
sets of plasmids or shRNA against YAF2. Representative blots of three independent experiments
shYAF2-expressing HCT116 cells were transfected with increased amounts of Myc-PDCD5 plasmi
dependent experiments are shown. (H) Knockdown of PDCD5 eliminated the positive effect of Y
creased amounts of Flag-YAF2 plasmids and immunoblotted with the indicated set of antibodies.2.7. Site-direct mutagenesis
Various mutants were created using the QuickChange kit (Agilent
Technologies, Santa Clara, CA, USA). PCR cycling conditions used inss. (A) YAF2 selectively increases the levels of PDCD5 protein. HCT116 (TP53+/+) cells were
side (ET) for 6 h. The immunoprecipitation assay was carried out with PDCD5 antibody. Rep-
ractions between PDCD5 and YAF2. Cells were immunoprecipitated with anti-YAF2 or anti-
ts of three independent experiments are shown. (C) PDCD5 speciﬁcally interacts with YAF2,
munoprecipitatedwith anti-Myc, and subsequently immunoblottedwith indicated antibod-
ot the PDCD5-interacting defective mutant YAF2ΔPDCD5, increases PDCD5 protein levels. Cells
the indicated antibodies. Representative blots of three independent experiments are shown.
d sets of YAF2 plasmids. In situ PLA analysis was performed as described in Materials and
m. (F) Knockdown of YAF2 reduces PDCD5 levels. Cells were transfected with the indicated
are shown. (G) PDCD5 overcomes the knockdown effect of YAF2 on TP53 activation. Stable
ds and immunoblotted with the indicated set of antibodies. Representative blots of three in-
AF2 on TP53 activation. Stable shPDCD5-expressing HCT116 cells were transfected with in-
Representative blots of three independent experiments are shown.
1064 S.-Y. Park et al. / Biochimica et Biophysica Acta 1853 (2015) 1060–1072site-directed mutagenesis were 18 cycles of ampliﬁcation with the
following reaction: denaturation at 94 °C for 30 s, annealing at
55 °C for 1min, and extension at 68 °C for 10min. Ampliﬁedmixtures
were treated with DpnI (Agilent Technologies) at 37 °C for 1 h and al-
iquots were used to transform competent E. coli. All constructs were
conﬁrmed by DNA sequencing.
2.8. In vivo ubiquitination assay
HCT116 cells were co-transfectedwith HA-Ub plasmid, Myc-PDCD5,
and Flag-YAF2. After 48 h, whole cell lysates were treated with MG132
for 6 h and subsequently processed for immunoprecipitation with anti-
Myc antibody. Ubiquitination of Myc-PDCD5was visualized byWestern
blotting with anti-HA antibody.
2.9. TP53 oligomerization assay
Cells were lysed with lysis buffer and immunoprecipitated with
indicated tagged antibody or TP53 antibody with agarose A/G
beads (Santa Cruz). Agarose beads were washed with PBS, and glu-
taraldehyde (Sigma-Aldrich) was added to the immunoprecipitants
at indicated concentrations. After incubating for 20 min at 37 °C,
the reactions were stopped by adding 2× loading buffer, and the
samples were heated at 100 °C for 5 min and resolved by SDS-
PAGE. Immunoblot analysis was performed with anti-TP53 or indi-
cated tagged antibody.
2.10. Duo Link in situ proximity ligation assay (PLA)
Duo Link in situ PLA analysis was performed according to the
manufacturer's instructions (Sigma-Aldrich). In short, paraformal-
dehyde-ﬁxed cells were washed with PBS, incubated for 15 min in
1.5% hydrogen peroxide, washed, and blocked with blocking solution.
Primary rabbit antibody was applied, and the cells were incubated
with PLUS and MINUS secondary PLA probes against rabbit IgG only or
against both rabbit and mouse IgG. The incubation was followed by hy-
bridization and ligation, and then ampliﬁcation was performed. After
mounting with Duo Link mounting medium, the samples were exam-
ined using a Zeiss LSM700 confocalmicroscope (Carl Zeiss, Oberkochen,
Germany).
2.11. MTT assay
Cell viability was determined with the conventional MTT reduction
assay. First, 5 × 103–1 × 104 cells were seeded in a 96-well plate. After
overnight incubation, cells were transfected with indicated plasmids
for 30 h, and the cells were treated with 50 μM ET for another 48 h.
Cells were then treated with 15 μM MTT solution (2 mg/ml) for
90min at 37 °C, the formation of formazanwas resolvedwith DMSO so-
lution for 30minwith shaking. The absorbancewas recorded at 570nm,
and a reference was recorded at 630 nm with a microplate reader
(Model 550, BIO-RAD Laboratories, Hercules, CA, USA).Fig. 3. YAF2 promotes TP53 activation via PDCD5. (A) Knockdown of YAF2 impairs the inducti
shRNAs andwere stimulatedwith 50 μMET. Representative blots of three independent experim
of ET on TP53 pathway activation when compared with PDCD5 or YAF2 alone. HCT116 cells we
bodies. Representative blots of three independent experiments are shown. (C) Association of YA
were transfectedwith the indicated set of plasmids and immunoblottedwith indicated antibodi
of indicated genes were analyzed by real-time PCR (upper panel). The results are shown asmea
with+ET). (D) YAF2 fails to overcome the knockdown effect of PDCD5 on TP53 pathway activa
plasmids and immunoblottedwith indicated antibodies (lower panel). Representative blots of t
time PCR (upper panel). The results are shown as means ± SD calculated from three independ
comes the knockdown effect of YAF2 on TP53 pathway activation. Stable shYAF2-expressingHC
indicated antibodies (lower panel). Representative blots of three independent experiments are s
are shown as means ± SD calculated from three independent experiments. (*P b 0.05 vs.−ET2.12. TUNEL assay
For the detection of apoptosis in cells, DNA fragmentation was eval-
uated by a TUNEL assay using the HT Titer TACS Assay Kit (Trivigen,
Gaithersburg, MD, USA) according to the manufacturer's instructions.
Brieﬂy, the cells were ﬁxed with 3.7% buffered formaldehyde solution
for 7 min, washed with PBS, permeabilized with 100% methanol for
20 min, washed with PBS twice, digested with proteinase K for
15 min, quenched with 3% hydrogen peroxide, washed with distilled
water, labeled with deoxynucleotidyl transferase, incubated at 37 °C
for 90 min, and then treated with stop buffer. The cells were incubated
with TACS-Sapphire substrate, and the colorimetric reaction was
stoppedwith 0.2 NHCl after 30min. The colorimetric reactionwasmea-
sured in a microplate reader at absorbance 450 nm.
2.13. Xenograft experiments
A suspension of 2 × 105 A549 cells in 100 μl PBS was injected subcu-
taneously into the right ﬂank of 5-week-old athymic BALB/c nu/numice
(Orient, Seoul, Korea). Each experimental group included eight mice.
Tumor size was monitored closely and measured every 7 days using a
caliper. Two weeks after injection, mice with comparable-sized tumors
(~200 mm3) were selected for treatment with ET (10 mg/kg) at 2-day
intervals for ﬁve weeks. After ﬁve weeks of ET treatment, mice were
sacriﬁced, and tumors were harvested, photographed, and weighed.
The volume of tumors was estimated using the formula: Volume =
½ × a × b2, where (a) and (b) represent the largest and smallest diam-
eters, respectively. Animal studies were performed after obtaining ap-
proval according to the guidelines of the Institutional Animal Care
committee of the Ulsan College of Medicine.
2.14. Statistical analysis
Statistical signiﬁcance was examined using Student's t-tests. The
two-sample t test was used for two-group comparisons. Valueswere re-
ported as means ± standard deviations (SD). P values b 0.05 were con-
sidered signiﬁcant.
3. Results
3.1. YAF2 selectively binds to and increases PDCD5 protein levels
To explore the regulatorymechanismof PDCD5 function duringDNA
damage response, we ﬁrst dissected the PDCD5 interactome using yeast
two-hybrid assays. Because an elevated level of PDCD5 mRNA was re-
ported in the mouse testis [15], a human testis cDNA library was used
for this analysis (Supplementary Table S1). Among the putative
PDCD5-interacting proteins, we found that PDCD5 strongly interacts
with four proteins including ATP1B1, ARRDC5, PLSCR2, and YAF2 (Sup-
plementary Fig. S1). Importantly, overexpression of YAF2 selectively in-
creased PDCD5 protein levels in response to etoposide (ET) when
compared with other PDCD5-interacting proteins (Fig. 1). We also ver-
iﬁed the endogenous interaction between PDCD5 and YAF2 (Fig. 1B).on of PDCD5 and TP53 in response to ET. Cells were transfected with the indicated sets of
ents are shown. (B) Co-expression of PDCD5with YAF2 synergistically enhances the effect
re transfected with the indicated set of plasmids and immunoblotted with indicated anti-
F2 with PDCD5 is required for activation of PDCD5 and TP53 response to ET. HCT116 cells
es (lower panel). Representative blots of three independent experiments are shown. Levels
ns± SD calculated from three independent experiments. (*P b 0.05 vs.−ET; #P b 0.05 vs.
tion. Stable shPDCD5-expressingHCT116 (TP53+/+) cells were transfectedwith Flag-YAF2
hree independent experiments are shown. Levels of indicated geneswere analyzed by real-
ent experiments. (*P b 0.05 vs.−ET; #P b 0.05, ##P b 0.01 vs. with +ET). (E) PDCD5 over-
T116 (TP53+/+) cells were transfectedwithHA-PDCD5 plasmids and immunoblottedwith
hown. Levels of indicated geneswere analyzed by real-time PCR (upper panel). The results
; #P b 0.05 vs. with +ET; **P b 0.05 vs. +ET + shYAF2).
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1066 S.-Y. Park et al. / Biochimica et Biophysica Acta 1853 (2015) 1060–1072PDCD5 speciﬁcally interacts with YAF2, but not its paralog RYBP, which
was found to participate in apoptosis [33], again verifying a speciﬁc in-
teraction between YAF2 and PDCD5 (Fig. 1C). Mapping analysisdemonstrated the N-terminal domain (31–60 a.a.) of YAF2 interacted
with PDCD5 (Supplementary Fig. S2A). Overexpression of a PDCD5-
interaction defective mutant, YAF2ΔPDCD5, had no effect on PDCD5
1067S.-Y. Park et al. / Biochimica et Biophysica Acta 1853 (2015) 1060–1072protein levels when compared with wild-type YAF2WT, suggesting the
interaction between YAF2 and PDCD5 is required for increased PDCD5
levels (Fig. 1D).Moreover, in situ proximity ligation assay (PLA) analysis
again conﬁrmed the interaction between PDCD5 and YAF2 proteins.
However, PDCD5 again failed to interact with a PDCD5-interaction de-
fective mutant, YAF2ΔPDCD5 (Fig. 1E). Since overexpression of YAF2 in-
creased PDCD5 protein levels, we next tested the knocking-down
effect of YAF2 onPDCD5protein levels. Knockdownof YAF2 reduced en-
dogenous PDCD5 levels (Fig. 1F). Because PDCD5 levels positively corre-
lated with those of TP53, we next examined the knockdown effect of
YAF2 on PDCD5-induced TP53 activation. Interestingly, overexpression
of PDCD5 efﬁciently overcame the knockdown effects of YAF2 on TP53
levels and the expression of TP53 target genes (Fig. 1G). However,
knockdown of PDCD5 abrogated the overexpression effect of YAF2 on
TP53 activation (Fig. 1H). These data indicate that YAF2 promotes
TP53 activation via association with PDCD5.
3.2. YAF2 stabilizes PDCD5 by inhibiting ubiquitination of PDCD5
Because YAF2 enhances PDCD5 expression, we next examined if
YAF2 increases the stability of PDCD5 in response to genotoxic stress.
Treatment with MG132 efﬁciently increased PDCD5 levels, whereas
the knockdown of YAF2 diminished the effect of MG132 on the stabi-
lization of PDCD5 proteins (Fig. 2A). A time-course experiment with
cycloheximide (CHX) treatment showed that YAF2 enhances PDCD5
stability (Fig. 2B). Notably, YAF2 knockdown led to reduced PDCD5
stability, but not reduced PDCD5mRNA levels, indicating YAF2's crit-
ical role in PDCD5 stabilization (Fig. 2C and D). Because overexpres-
sion of YAF2 greatly increased PDCD5 protein stability, we next
investigated if YAF2 increases PDCD5 stability by inhibiting the
ubiquitin-dependent proteosomal degradation pathway. As shown
in Fig. 2E, overexpression of wild-type YAF2 substantially reduced
the ubiquitination of PDCD5. However, overexpression of mutant
YAF2ΔPDCD5 failed to reduce the levels of PDCD5 ubiquitination
(Fig. 2E). Furthermore, we also observed that knockdown of YAF2
signiﬁcantly diminished PDCD5 stabilization by other DNA damage
reagents such as doxorubicin and cisplatinin, indicating the common
role of YAF2 in genotoxic stress-induced PDCD5 stabilization
(Fig. 2F). Collectively, these data suggest that YAF2 stabilizes
PDCD5 by inhibiting ubiquitination of PDCD5.
3.3. YAF2 promotes TP53 activation via PDCD5
Because both PDCD5 and TP53 are robustly induced by DNA damage
[29], we next investigated if YAF2 expression is also induced by ET treat-
ment. Similar to PDCD5, YAF2was induced at the early phase of ET treat-
ment when compared with TP53. Interestingly, knockdown of YAF2
greatly delayed the induction of PDCD5 and TP53 response to ET, indi-
cating that YAF2 induction is required for PDCD5 and TP53 activation
(Fig. 3A). Importantly, co-expression of PDCD5with YAF2 synergistically
enhanced the effect of ET on TP53 expression when compared with
PDCD5 or YAF2 alone (Fig. 3B). However, mutant YAF2ΔPDCD5 failed to
enhance the expression and transcriptional activity of TP53 upon ET
treatment (Fig. 3C). Since we observed that overexpression of YAF2
failed to overcome the knockdown effect of PDCD5 on TP53 activation,Fig. 4. YAF2 enhances the TP53 oligomerization via PDCD5. (A) Knocking-down of PDCD5 di
HCT116 (TP53+/+) cells were transfected with indicated plasmids and immunoblotted with t
were immunoprecipitated with anti-TP53 antibody. Immunoprecipitants were washed with P
by immunoblotting with anti-TP53 antibody. Representative blots of three independent experim
oligomerization of TP53. HCT116 cells were transfected with indicated plasmids and treated w
cross-linked using 0.01% glutaraldehyde. The oligomerization of TP53 was analyzed by immuno
are shown. (C) Overexpression of wild-type YAF2, but not of mutant YAF2ΔPDCD5, enhances ET
above. Representative blots of three independent experiments are shown. (D) Knockdown of P
shPDCD5-expressing HCT116 cells were transfectedwith the Flag-YAF2 plasmid. The oligomeri
experiments are shown. (E) PDCD5 overcomes the knockdown effect of YAF2 on TP53 oligome
tibody. Representative blots of three independent experiments are shown.we thus examined if YAF2 promotes TP53-mediated genotoxic stress re-
sponses via PDCD5. Overexpression of YAF2 failed to reverse the knock-
down effect of PDCD5 on ET-induced TP53 activation (Fig. 3D).
However, PDCD5 efﬁciently overcame the knockdown effect of YAF2
on ET-induced TP53 activation, indicating that YAF2 activates TP53 via
PDCD5 (Fig. 3E).
Tetramerization of TP53 is essential for DNA-binding, protein–pro-
tein interactions, post-translational modiﬁcations, and stabilization of
TP53 [34]. We intriguingly found that PDCD5 possesses a putative
double-strand DNA-binding domain (8–49 a.a.) by structure analysis of
PDCD5 protein using the Conserved Domain Database (NCBI) [35] (Sup-
plementary Fig. S3A). Because YAF2 promotes TP53 stabilization via
PDCD5, we tested if YAF2 enhanced ET-induced TP53 tetramerization
via PDCD5. Although ET robustly induced TP53 tetramerization, knock-
down of PDCD5 fully abrogated ET-induced TP53 tetramerization
(Fig. 4A). Co-expression of PDCD5 with YAF2 signiﬁcantly enhanced
ET-induced TP53 tetramerization (Fig. 4B). Importantly, mutant
YAF2ΔPDCD5 failed to enhance TP53 tetramerization compared with
wild-type YAF2, indicating that YAF2 promotes TP53 tetramerization
via association with PDCD5 (Fig. 4C). Furthermore, knockdown of
PDCD5 abolished the overexpression effect of YAF2 on ET-induced
TP53 tetramerization (Fig. 4D). Conversely, overexpression of PDCD5
efﬁciently reversed the knockdown effect of YAF2 on ET-induced TP53
tetramerization (Fig. 4E). Collectively, these data indicate that YAF2
promotes TP53-mediated genotoxic stress responses via PDCD5.
3.4. Depletion of PDCD5 abrogates YAF2-mediated TP53 activation
We further validated our ﬁndings using Pdcd5-depletedmouse em-
bryonic ﬁbroblast (MEF) cells by generating Pdcd5ﬂox/ﬂoxmice (Supple-
mentary Fig. S3). Fibroblasts generated from thesemicewere subjected
to adenovirus-expressing Cre recombinase (Ad-Cre) infection to delete
PDCD5 and to generate Pdcd5−/− MEFs. As expected, ET treatment
failed to induce TP53 stabilization and activation in Pdcd5−/− MEF
cells compared with Pdcd5+/+ MEF cells (Fig. 5A). Although YAF2 en-
hancedET-inducedPDCD5 stabilization and TP53 activation, genetic de-
pletion of PDCD5 reversed the positive action of YAF2 on PDCD5
stabilization (Fig. 5A). Conversely, reintroduction of PDCD5 in
Pdcd5−/−MEF cells dramatically restored YAF2 function in promoting
TP53 activation (Fig. 5B). To further validate the functional importance
of PDCD5 in TP53 activation, we assessed the activity of well-known
TP53 activators in the presence or absence of PDCD5. ET failed to in-
crease TP53 activation in the absence of PDCD5. Importantly, the disso-
ciation of MDM2 from TP53 by nutlin-3a had a negligible effect on TP53
activation in the absence of PDCD5, indicating that PDCD5 is required
for TP53 activation. Moreover, treatment with another TP53 activator,
tenovin-6, displayed the same result as nutlin-3a and ET treatment
(Fig. 5C). As we mentioned above, PDCD5 possesses a putative DNA
binding domain and its knocking-down impaired TP53 tetramerization
in response to ET, we next explored the possibility that PDCD5mediates
TP53 recruitment to the promoter region of target genes.We performed
chromatin immunoprecipitation (ChIP) analyses of the TP53-binding
site (TP53-RE) on Bax, which showed that the restoration of PDCD5 in
Pdcd5−/−MEF cells rescued the ET-induced recruitment of the TP53-
p300 complex to the TP53-binding site of its target genes. However,minishes TP53 oligomerization in response to ET treatment. Stable shPDCD5-expressing
he respective antibodies. For TP53 oligomerization assays, the same amounts of proteins
BS and cross-linked using 0.001% glutaraldehyde. Oligomerization of TP53 was analyzed
ents are shown. (B) Synergistic effect of PDCD5 and YAF2 on the etoposide (ET)-induced
ith ET for 6 h. Whole cell lysates were immunoprecipitated with anti-TP53 antibody and
blotting with anti-TP53 antibody. Representative blots of three independent experiments
-induced oligomerization of TP53. The oligomerization of TP53 was analyzed as described
DCD5 abrogates the enhancing action of YAF2 on ET-induced TP53 oligomerization. Stable
zation of TP53was analyzed as described above. Representative blots of three independent
rization. The oligomerization of TP53 was analyzed by immunoblotting with anti-TP53 an-
Fig. 5.Depletion of PDCD5 eliminates YAF2-mediated TP53 activation. (A) Depletion of PDCD5 abrogates the effect of YAF2 on etoposide (ET)-induced TP53 activation. Pdcd5f/f MEF cells
following infection with either Ad-Cre or Ad-GFP were established and electroporated with the Flag-YAF2 plasmid. After 24 h, MEF cells were treated with 50 μMET and subjected to im-
munoblotting with indicated antibodies. Control undeleted cells are denoted Pdcd5f/f, and Pdcd5-deleted cells are denoted Pdcd5−/−. Representative blots of three independent experi-
ments are shown. (B) Restoration of PDCD5 returns the function of YAF2 in promoting TP53 activation. Pdcd5−/−MEF cells were electroporated with indicated plasmids and treatedwith
ET.Whole cell lysateswere immunoprecipitatedwith indicated antibodies. Representative blots of three independent experiments are shown. (C) PDCD5 is required for TP53 activation in
response to multiple TP53 activators. Pdcd5f/f MEF cells following infection with either Ad-Cre or Ad-GFPwere established and treatedwith indicated TP53 activators (ET: 50 μM; Nutlin-
3a: 10 μM; Teonovin-6: 10 μM). Representative blots of three independent experiments are shown. (D) Restoration of PDCD5 induces recruitment of the TP53-p300 complex to the pro-
moter region of Bax in response to ET. Pdcd5−/−MEF cells were electroporated with indicated plasmids and then treated with ET. ChIP assays were performed with the indicated anti-
bodies. Precipitated samples were analyzed by real-time PCR, and results are presented as the percentage of input. The results are shown as means ± SD calculated from three
independent experiments. (*P b 0.05, **P b 0.01 vs. + ET).
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PDCD5ΔYAF2 had no effect on TP53 recruitment to target genes in the ab-
sence of PDCD5, suggesting that PDCD5 mediates TP53 tetramer re-
cruitment to pro-apoptotic genes upon genotoxic stress (Fig. 5D and
Supplementary Fig. S2B). Interestingly, Flag-tagged PDCD5, but not
YAF2, was recruited to the TP53-binding site of target genes with
TP53 and p300. Taken together, these results indicate PDCD5 is required
for TP53-mediated transcriptional activation of pro-apoptotic genes.
3.5. YAF2 facilitates in vivo genotoxic stress responses in a PDCD5-
dependent way
To corroborate the crucial role of PDCD5 in genotoxic stress-induced
apoptosis, we performed a TUNEL assay in the knockdown of PDCD5
and found ET treatment dramatically increased DNA damage, although
knockdown of PDCD5 diminished the effect of ET on apoptosis of A549
cells. YAF2 failed to restore the inhibitory effect of ET on the growth of
A549 cells in the PDCD5 knockdown (Fig. 6A), but PDCD5 efﬁciently
overcame the knockdown effect of YAF2 on ET-induced apoptosis of
A549 cells (Fig. 6B). We next examined the functional consequences
of the YAF2-PDCD5 network regarding tumorigenic growth of cancer
cells. In response to ET treatment, the growth of A549 lung cancer
cells was greatly suppressed; however, knockdown of PDCD5 dimin-
ished the effect of ET on the suppression of A549 cancer cell growth.
YAF2 failed to restore the inhibitory effect of ET on the growth of
A549 cells in the PDCD5 knockdown (Fig. 6C). Conversely, PDCD5 efﬁ-
ciently overcame the knockdown effect of YAF2 on ET-induced suppres-
sion of A549 cell growth (Fig. 6D).
Finally, to solidify our ﬁnding, we performed reconstitution ex-
periments after generating the TP53-interacting, PDCD5-defective
mutant and the YAF2-interacting, PDCD5-defective mutant. Based
on the mapping analysis among PDCD5, YAF2, and TP53, we next
generated various PDCD5 point mutants by site-directed mutagene-
sis (Supplementary Fig. S3A). Each myc-tagged PDCD5 point mutant
was co-transfected with Flag-YAF2 or Flag-TP53, and then each
PDCD5-defective mutant was screened by immunoprecipitation
analysis. Notably, each PDCD5-defective mutant selectively failed
to interact with the respective proteins (Supplementary Fig. S3B).
ET had no effect on cell viability and DNA damage in Pdcd5-
depleted MEFs; however, restoration of PDCD5WT in Pdcd5−/−
MEF cells led to substantial genotoxic stress-induced DNA damage.
Importantly, restoration of PDCD5E16D(TP53) and PDCD5E16D(YAF2)
did not induce the DNA damage and cell death, verifying the apopto-
tic signaling cascade consists of YAF2, PDCD5, and TP53 (Fig. 6E).
Furthermore, in vivo tumorigenicity assays using subcutaneous in-
jection of A549 cells into nude mice demonstrated that reduction
of PDCD5 signiﬁcantly enhanced the chemoresistance of A549
cells. However, restoration of wild-type PDCD5, but not of PDCD5-
E16D or PDCD5E16D, markedly reversed the chemoresistance of
PDCD5-depleted A549 cells (Fig. 6F). These data collectively demon-
strate that the YAF2 facilitates genotoxic stress response via PDCD5.
4. Discussion
Imbalanced levels of intracellular apoptotic proteins are common
in cancer cells. Therefore, understanding apoptosis signaling pro-
teins in cancer cells may lead to the development of potential anti-
cancer strategies. In our present study, we identiﬁed YAF2 as
PDCD5-interacting partner. The YAF2 protein was originally identi-
ﬁed as the binding partner of Yin-Yang-1 (YY-1) transcriptional fac-
tor with YY-1 and E4TF1/hGABP-associated factor-1 [36]. According
to a yeast three-hybrid assay, YAF2 positively regulates the tran-
scriptional activity of E4TF1, a sequence-speciﬁc transcription factor,
that regulates cytochrome c oxidative subunits IV and Vb, the ATP
synthase β-subunit, ribosomal proteins L30 and L32, and the retino-
blastoma tumor suppressor proteins [37]. In addition, YAF2 is a pro-oncogene Myc- and MycN-associated protein and inhibits Myc-
mediated transactivation and transformation [38]. These results col-
lectively demonstrate the crucial roles of YAF2 as a cofactor during
transcriptional regulation. Conversely, limited information exists re-
lated to the role of YAF2 during apoptosis. During zebraﬁsh embryo-
genesis, YAF2 inhibited caspase-8-mediated apoptosis and induced
cell survival [39], but we here found much evidence that YAF2 acts
as a pro-apoptotic regulator in cancer cells. First, YAF2 was robustly
induced and interacts with PDCD5 in response to ET. Second, knock-
down of YAF2 greatly diminished genotoxic stress-induced PDCD5
stabilization and TP53 activation. Third, YAF2 enhanced the activa-
tion of TP53 and cellular apoptosis via PDCD5. The RYBP (RING1
and YY-1 binding protein) is a human paralog of YAF2 and has a func-
tional form distinct from YAF2 during its transcriptional regulation
of Polycomb target genes [40]. In addition to a transcription factor,
RYBP inhibits ubiquitination and degradation of TP53 via interaction
with MDM2 [33]. In our study, we observed a similar action of YAF2
by its mediation of PDCD5 and TP53 interaction during apoptosis.
Considering the functional differences of the two homologs, both
YAF2 and RYBP may form different protein complexes during apo-
ptosis. With regard to this possibility, we veriﬁed that PDCD5 selec-
tively interacts with YAF2 but not with RYBP. Based on these
ﬁndings, we suggest that YAF2 acts as an apoptosis-facilitating mol-
ecule by mediating protein–protein interaction upon genotoxic
stress.
TP53 is known to mediate cell fate decision depending on the inten-
sity of stress between survival and death. Upon DNA damage, TP53 ar-
rests the cell cycle and facilitates DNA repair. If the damage is beyond
repair, TP53 promotes the expression of pro-apoptotic genes such as
Bax and Puma to trigger apoptosis. For TP53-mediated cell fate decision,
diverse TP53 cofactors such as HIPK2, DYRK2, PCAF, and E4F1 are in-
volved in the decision-making process [41]. Thus, TP53 make cell fate
decision upon cellular stresses, at least in part, through interaction
with speciﬁc cofactors. It has been shown that PDCD5 is rapidly up-
regulated and translocated into nucleus to promote DNA damage re-
sponse [28]. Based on our time-course experiments, both YAF2 and
PDCD5 are induced at the early phase of ET treatment (2 h) when com-
pared to TP53. Knocking-down of either YAF2 or PDCD5 greatly reduced
the TP53 activation in a response to genotoxic stress. Moreover, ChIP as-
says displayed that PDCD5 is recruited to the promoter region of BAX
with TP53. Thus, it is likely that the stabilization of PDCD5 by YAF2
may occur before TP53 stabilization, and then nuclear localized PDCD5
interacts with TP53 to facilitate apoptosis upon prolonged genotoxic
stress. Further work would be necessary to determine the speciﬁc mo-
lecular dynamics amongYAF2, PDCD5, and TP53 during genotoxic stress
responses.
In summary, we have described the molecular mechanism by
which the YAF2 positively regulates PDCD5 function upon genotoxic
stress responses. In this pathway, YAF2 stabilizes PDCD5 by
inhibiting the ubiquitin-dependent proteosomal degradation path-
way, which subsequently leads to TP53 activation. Importantly, we
found that YAF2 promotes the TP53 pathway in a PDCD5-
dependent manner, highlighting the critical role of PDCD5 in TP53-
mediated genotoxic stress responses (Fig. 6G). Our ﬁndings reveal
a previously undiscovered PDCD5 network that acts as a central
hub in the regulation of genotoxic stress responses. Thus, alteration
of this PDCD5 network in cancer cells might contribute to tumori-
genesis. Further understanding of the clinical relevance of this
YAF2-PDCD5 cascade to human tumorigenesis may provide a poten-
tial promising target for cancer therapy.Transparency Document
Transparency Document associatedwith this article can be found, in
the online version.
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